Jul 25, 2017
Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper